Pediatrix Therapeutics Announces Close Of Series A Financing Round

(VCBeat) Apr. 26, 2021 -- Pediatrix Therapeutics, a Chinese company focused on pediatrics, announced that it has completed its Series A funding round. Pediatrix Therapeutics was founded by Eight Roads, F-Prime Capital, and Hongyuan Capital to address unmet clinical needs in the pediatric medicine market in China. The company is committed to the development and introduction of effective and clinically proven drugs for children to provide high-quality and affordable treatments for children and families in China. The funds raised in this round will be used to expand the R&D team and develop the product pipeline with medicines for children as the core.

In recent years, relevant departments have introduced a number of policies and measures to encourage the R&D and production of children's drugs. The Outline of "Healthy China 2030" emphasizes that the purpose of drug development for children is to provide safe, effective, quality-controlled drugs suitable for children at different ages.

With the continuous improvement and growth of relevant policies and market demand, Pediatrix Therapeutics sees a great opportunity for the development of the children's medicine market. With the industry experience of its management and expert team, as well as the resource network of its investors, Pediatrix Therapeutics is committed to the research, development and introduction of high-quality and clinically proven drugs for children. The company aims to build a dedicated pediatric ecosystem to address the significant unmet clinical needs of the Chinese market.

Since 1969 Eight Roads have been partnering with ambitious technology and healthcare founders from all across the world. Its global ventures platform is one of the largest in the world, with teams investing in Asia, Europe, Israel and the US. With over 25 years of venture capital experience in China and has invested in more than 110 companies in the healthcare sectors. In the last 10 years, It has invested nearly $6 billion in startups worldwide.

F-Prime Capital was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. 

In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai.